In a significant move to bolster research and innovation in India’s pharmaceutical and medical technology sectors, the Department of Pharmaceuticals, Government of India, organized an Industry Dialogue in Bengaluru on March 25, 2025. The event brought together key representatives from the industry, startups, and research institutions, including officials from the Indian Council for Medical Research (ICMR), Council of Scientific and Industrial Research (CSIR), and innovation platforms such as the Centre for Cellular and Molecular Platforms (C-CAMP). The aim was to foster collaboration and explore how government-backed initiatives could further accelerate research and development (R&D) in the country.

The dialogue provided in-depth insights into the Promotion of Research and Innovation in the Pharma-MedTech Sector (PRIP) Scheme, alongside other key initiatives supporting innovation. Programmes such as ICMR’s Patent Mitra, MedTech Mitra, and the Indian Clinical Trial and Education Network (INTENT) were discussed extensively. These initiatives play a crucial role in guiding startups and researchers through the patent filing process, enabling clinical trials, and facilitating the commercialization of research outcomes. Furthermore, CSIR’s Innovation Complex and C-CAMP’s incubation facilities were highlighted as vital components in translating scientific research into market-ready products.

Addressing the gathering, Shri Amit Agrawal, Secretary of the Department of Pharmaceuticals, emphasized India’s growing role in strengthening global supply chains. He urged stakeholders to move beyond "Make in India" toward a vision of "Innovate in India and Make for the World," positioning the country as a global hub for innovation and manufacturing.

Breakout sessions during the event saw active participation from startups, industry leaders, and academia, who provided valuable feedback on emerging R&D trends and strategies to enhance collaboration between industry and research institutions. Participants also discussed ways to maximize funding opportunities and scale up innovative projects to drive sustainable growth in the sector.

To ensure inclusive and industry-aligned implementation of the PRIP Scheme, stakeholders were encouraged to submit detailed feedback and project proposals through the Expression of Interest (EoI) form available on the Department of Pharmaceuticals' website. The EoI will remain open until April 7, 2025, providing an opportunity for industry voices to shape the scheme’s future direction.

This collaborative approach marks a significant step towards strengthening India’s innovation ecosystem and positioning the country at the forefront of pharmaceutical and MedTech advancements on the global stage.